Combination vaccine of dendritic cells (DCs) and T cells effectively suppressed preestablished malignant melanoma in mice.
The study aims at establishing a novel vaccine procedure, using bone marrow-derived DCs that have ingested apoptotic B16 melanoma (DCs(+)), alone or in combination with splenic T lymphocytes from a syngenic donor. Co-immunization with DCs(+) and T cells showed the highest antitumor potential against preestablished B16 tumor in mice, in which CTL and NK cytotoxicities were drastically elevated, while either DCs(+) alone, naive DCs (DCs(-)) alone, or a mixture of DCs(-) and T cells induced less significant therapeutic outcomes. Use of extracellular matrix proteins elevated antitumor activity of DC(-)/T cell vaccine. Compared with the CD8(+) cells, the CD4(+)T cells more remarkably improved the efficacy of DC-based immunotherapy. The present system may be a feasible therapeutic modality to eradicate malignancies including melanoma.
Asada
Hidetsugu
H
Department of Biotechnology, Faculty of Engineering, Kyoto Sangyo University, Kyoto 603-8555, Japan.
Kishida
Tsunao
T
Hirai
Hideyo
H
Shin-Ya
Masaharu
M
Imanishi
Jiro
J
Takeuchi
Minoru
M
Mazda
Osam
O
D000818:Animals; D000951:Antigens, Neoplasm / Q000276:immunology*; D000964:Antimetabolites, Antineoplastic; D017209:Apoptosis; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology / Q000637:transplantation; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology / Q000637:transplantation; D019496:Cancer Vaccines / Q000276:immunology / Q000627:therapeutic use*; D045744:Cell Line, Tumor; D003713:Dendritic Cells / Q000276:immunology / Q000637:transplantation*; D016326:Extracellular Matrix Proteins / Q000276:immunology; D005260:Female; D016219:Immunotherapy, Adoptive / Q000379:methods; D007694:Killer Cells, Natural / Q000276:immunology; D008546:Melanoma, Experimental / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D051379:Mice; D008810:Mice, Inbred C57BL; D011691:Puromycin; D013601:T-Lymphocytes / Q000276:immunology / Q000637:transplantation*; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology; D014185:Transplantation, Isogeneic
D000951:Antigens, Neoplasm; D000964:Antimetabolites, Antineoplastic; D019496:Cancer Vaccines; D016326:Extracellular Matrix Proteins; D011691:Puromycin